The regulatory role of DPP4 in atherosclerotic disease

• Main Authors: Lihua Duan, Xiaoquan Rao, Chang Xia, Sanjay Rajagopalan, Jixin Zhong
• Format: Article
• Language: English
• Published: BMC 2017-06-01
• Series: Cardiovascular Diabetology
• Subjects: Dipeptidyl peptidase; Gliptins; Atherosclerosis; Incretin; DPP4 inhibitor
• Online Access: http://link.springer.com/article/10.1186/s12933-017-0558-y

Abstract The increasing prevalence of atherosclerosis has become a worldwide health concern. Although significant progress has been made in the understanding of atherosclerosis pathogenesis, the underlying mechanisms are not fully understood. Recent studies suggest dipeptidyl peptidase-4 (DPP4), a regulator of inflammation and metabolism, may be involved in the development of atherosclerotic diseases. There has been increasing clinical and pre-clinical evidence showing DPP4-incretin axis is involved in cardiovascular disease. Although the cardiovascular outcome of DPP4 inhibition or incretin analogues has been or being evaluated by several large scale clinical trials, the exact role of DPP4 in atherosclerotic diseases is not completely understood. In the current review, we will summarize the recent advances in direct and indirect regulatory role of DPP4 in atherosclerosis.